Fig. 3From: A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myelomaProgression-free survival, duration of response and overall survival. Kaplan–Meier curves for PFS (a) and OS (c) of the 23 treated patients, and DOR (b) of the 20 patients who responded. The shaded region indicates the 95% CIBack to article page